模拟研究比较抗胆碱能药物与多重用药对死亡、痴呆和谵妄风险的影响
基于英国生物银行约20万中位年龄65岁人群数据,通过模拟药物负担量表比较抗胆碱能用药与多重用药对死亡、痴呆和谵妄的风险。抗胆碱能多重用药伪量表的比值比(死亡、痴呆、谵妄中位数1.09-1.10)高于一般多重用药伪量表(1.05-1.06),但超出多重用药的附加效应较小且依赖现有抗胆碱能负担量表(ABS)。
要点
- 抗胆碱能药物对死亡、痴呆、谵妄的风险超出多重用药,但附加效应较小。
- 35%-90%的现有ABS效应强于多数模拟量表,提示ABS依赖性。
- 抗胆碱能附加效应在调整模型及高龄用药者中更明显。
核心结论
- 抗胆碱能药物存在超越多重用药或药物数量的效应,但效应较小、依赖ABS且因结局而异。
主要发现
- 抗胆碱能多重用药伪量表(中位数1.09-1.10)的死亡、痴呆、谵妄比值比高于一般多重用药伪量表(1.05-1.06)。
- 35%-90%的现有ABS表现出比多数伪量表更强的效应。
关键数值与推荐
- 抗胆碱能多重用药伪量表比值比中位数1.09-1.10,一般多重用药伪量表1.05-1.06。
- 35%-90%的现有ABS效应强于多数伪量表。
临床怎么用
- 老年医学科评估多重用药时,应关注抗胆碱能药物负担,但其附加风险较小且因ABS和结局不同。
局限性
- 原文未报告具体局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy and use of anticholinergics are associated with adverse health outcomes. Because these 2 exposures covary, it is not known to what extent the detrimental health effects attributed to anticholinergic burden measured by anticholinergic burden scales (ABS) may be due to polypharmacy. METHODS: Our aims were to evaluate the added effect beyond polypharmacy of (1) anticholinergic use and (2) scores according to existing ABS. We used linked data from the UK Biobank prospective cohort study to investigate drugs prescribed in primary care in the year 2015 (n = ∼200 000; median age = 65 years). We randomly sampled among drugs to create 2000 pseudoscales-drug burden scales designed to reflect the strength of the background effect of polypharmacy. We differentiated pseudoscales constructed to capture either general polypharmacy or putative anticholinergic polypharmacy. For each scale, we fitted logistic regression adjusted for confounders to assess associations between pseudoscales from each set and risk of death, dementia, or delirium. We also assessed 23 existing ABS by comparing them to the effects of pseudoscales that included the same numbers of drugs as each ABS. RESULTS: Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06). The added effect of anticholinergic use beyond polypharmacy was greater in adjusted models and when prescribed to participants when they were older. 35%-90% of ABS exhibited stronger effects than most pseudoscales. CONCLUSIONS: The models show an anticholinergic effect of drugs beyond polypharmacy or drug count, but it is small, ABS-dependent, and varies between outcomes.
引用
- Mur J, Stirland LE, Muniz-Terrera G, et al. A simulation study comparing anticholinergic drug use with polypharmacy for risk of death, dementia, and delirium in UK Biobank. J Gerontol A Biol Sci Med Sci. 2025. PMID: 41128551. doi:10.1093/gerona/glaf232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。